Drug
Uprosertib
Uprosertib is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
100%(3 trials)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
active_not_recruiting125%
completed375%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
NCT01979523
completedphase_1
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
NCT01902173
completedphase_2
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01989598
completedphase_1
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01935973
Clinical Trials (4)
Showing 4 of 4 trials
NCT01979523Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
NCT01902173Phase 1
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
NCT01989598Phase 2
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01935973Phase 1
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4